Guideline-Directed Medical Therapy in HF – Evidence vs. Practicality
Tune into this episode to hear a discussion on GDMT and the gaps between the evidence and the practicality of implementation. They discuss the gap between trial-proven evidence-based heart failure therapies and implementation of these medications to our most vulnerable patients. Host Kevin Shah, MD, is joined by three HF providers across the career spectrum: Ted Berei, PharmD, Gregg C. Fonarow, MD, and Jonathan Davis, MD, MPH.
Listen below and subscribe: Apple Podcasts, Google Podcasts, Spotify, Podcast Home
Hosts:
- Kevin S. Shah MD, Assistant Professor of Medicine at the University Of Utah Heart Failure & Transplant Cardiology @KevinShahMD
Guests:
-
Ted Berei, PharmD, Clinical Pharmacist, General Cardiology/Advanced Heart Failure - University of Wisconsin Hospitals and Clinics @chfpharmd
-
Jonathan Davis, MD, MPH, Associate Professor, UCSF, Director of the Heart Failure Program, San Francisco Health Network (SFHN) @JonathanDavisHF
-
Gregg C. Fonarow, MD, FHFSA, Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA @gcfmd
Disclosures
- Ted Berei, PharmD - Consultant: Cytokinetics
- Jonathan Davis, MD, MPH - Consultant/Advisory Board: AstraZeneca
- Gregg C. Fonarow, MD, FHFSA - Consultant/Advisory Board: Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis